Overview

This is a joint event between the Royal College of Pathologists & Association of Clinical Pathologists.

This meeting highlights some of the most advanced recent developments, and shows some of the ways in which these developments are about to change patient care. This special meeting brings together pathologists, industry and world experts across a range of areas, to showcase innovations that are changing healthcare and diagnostics in the practice of pathology.

We not only have internationally renowned individuals who are at the cutting edge of developments such as hand held gene sequencers, scanning mass spectroscopy, and augmented reality, but also speakers who are putting real innovation into practice, both in the setting of clinical trials-as well as large scale clinical implementation.

The programme includes a ‘Path Dragon’ session where cutting edge start up and SMEs will pitch to the audience, and an expert panel.

The event is aimed at current and training pathologists who want to find out what they will be doing and dealing with in the near future, and how they can innovate and bring their innovations into practice.

Conference Drinks & Canape Reception: We will be hosting a drinks reception on the evening of Wednesday 10th October which is included in the registration fee, but please tick the relevant box to inform us of your attendance for catering purposes.  This will be a great opportunity to network with other delegates and the trade representatives.

If you wish us to reserve you a place until study or annual leave is arranged please email us and we'll organise that for you, but a full application and payment must be received in advance of the event to secure your attendance.

 

Programme

Wednesday 10 October 2018

From bench to reality – coming your way

09.00     Registration and Coffee

09.30     Welcome and Introduction – Professor Pat Twomey (ACP)/Professor Jo Martin (RCPath)

09.40     Hepatitis C from treatment to national eradication - Kohn Lecture – Professor Graham Foster (QMUL)

10.20     Blood Spots and Prison – Speaker TBC

10.50     Augmented and virtual reality – Professor Shafi Ahmed (Royal College of Surgeons)

11.30     Mid-morning refreshments

Scanning mass spectrometry

11.50     KEY Note: Imaging Mass Spectrometry – Possibilities in Pathology Kristina Schwamborn (Institute of Pathology, Munich)

12.35     Sample Preparation and Data Analysis Strategies for Mass Spec Imaging Dr Alice Ly (Bremen, Germany)

12.55     Lunch & networking

13.55     Innovation in the NHS – Professor Tony Young (Innovation NHS England)

14.35     Path Dragon – Start up and SMEs will pitch to the audience and an expert panel.

16.00     Path Dragon feedback

16.45     Closing comments – Professor Jo Martin (RCPath)

Conference drinks and canape reception and an opportunity to network with delegates and trade. From 5-7pm                                                                                                                                               

Thursday 11 October 2018

09.00     Arrival refreshments

09.30     Welcome – Professor Jo Martin (RCPath)

09.40     Gene Therapy for haemophilia- Cameron Lecture – Professor John Pasi (Queen Mary University of London)

10.20     Gene Therapy for thalassemia and sickle cell disease – Dr Paul Telfer (Barts Health NHS Trust)

10.50     Mid-morning refreshments

11.10     Machine Learning – Professor Peter Hamilton (Belfast)

11.50     From descriptive to predictive: innovation in clinical decision support Adj. Professor Okan Ekinci (Basel)

12.20     Lunch & networking

13.20     Hand held DNA Analysis – Associate Professor Matthew Loose (University of Nottingham)

Innovation and Entrepreneurism Masterclass   

Chair- Bridget Wilkins  

14.00     Regulation & innovation in devices and diagnostic tests - things to be aware of Stephen Lee, MHRA

14.45     Artificial intelligence in medical imaging - a start-up's journey – Dr Manoj Ramachandran (Barts Health NHS Trust)

15.30     Behaviour and psychology influencing the adoption and spread of innovation – Sasha Karakusevic (Horizons team, Strategy & innovation Directorate, NHS England)

16.00     Closing comments – Dr Bridget Wilkins (ACP)/Professor Jo Martin (RCPath)

 

Registration Fees
  • ACP Members  - Free (The ACP have subsidised a number of places free of charge for this event to be allocated on a first come, first served basis) Please note: Cancellations received after Friday 21st September 2018 or non-attendance on the day will incur a charge of £370.  Membership will be validated by the ACP.  If you wish to join the ACP, membership must be confirmed by the ACP in time for the 10th September Council Meeting to secure free registration for this event.  Please contact ACP - info@pathologists.org.uk
  • RCPath Fellows (who are not members of the ACP) - £370
  • RCPath Concessions - £190 (Trainees, BMS, Nurses, Retired)
  • Non-members - £425

Drinks & Canape reception attendance is included in the registration cost but please let us know through the booking process whether you are attending for catering purposes.

 

Location

To be held at the Royal College of Obstetricians and Gynaecologists,27 Sussex Place, London NW1 4RG

 

Speakers

Disruptive Technology

  • Kristina Schwamborn

    Kristina Schwamborn is a consultant at the Institute of Pathology, TU Munich, Germany. She received her M.D. from Heinrich-Heine-University in Dusseldorf, Germany. Dr. Schwamborn also holds a PhD from RWTH Aachen University for developing different proteomic assays in search for prostate and bladder cancer biomarkers. Between 2008-2010 she joined the group of Prof. Richard Caprioli in the Department of Biochemistry, Vanderbilt University to utilize imaging mass spectrometry in different clinical applications including diagnosis and risk stratification in prostate cancer. In 2010 she joined the Institute of Pathology, TU Munich and took her board examination in Anatomical Pathology in 2015.

     

  • Professor Patrick Twomey

    Patrick Twomey is consultant chemical pathologist in St. Vincent's University Hospital, Dublin, the Laboratory Director for Clinical Chemistry in St Vincent’s University Hospital and Clinical Professor in the School of Medicine, University College Dublin. He obtained an Intercalated BSc in Biochemistry from University College Cork before being awarded his Medical degree. He is a Fellow of both the Faculty of Pathology at the Royal College of Physicians of Ireland and of the Royal College of Pathologists where he also is an examiner. He is the Vice Chair of the UK Joint Working Group on Quality Assessment in Pathology and past Chair of the Chemical Pathology National Quality Assurance Advisory Panel within the Royal College of Pathologists. He is the Honorary Treasurer of the Faculty of Pathology, Royal College of Physicians of Ireland and Honorary Treasurer of the Association of Clinical Pathologists. He has co-authored one text book, several book chapters and over 80 original publications in the fields of clinical biochemistry, metabolic medicine, lipids and nutrition. He is a member of the editorial boards of the Journal of Clinical Pathology and of the British Medical Journal Case Reports.

  • Professor John Pasi

    Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary University of London. Honorary Consultant Haematologist, The Royal London Hospital, Barts Health NHS Trust, London, UK.

    John Pasi is Professor of Haemostasis and Thrombosis at The Royal London Hospital, Barts and the London School of Medicine and Dentistry and Haemophilia Centre Director.

    His clinical practice spans both adults and children and covers all aspects of haemostasis and thrombosis. His research interests cover many aspects of inherited and acquired bleeding and clotting disorders, particularly new bioengineered therapies for haemophilia, novel therapies for haemophilia including gene therapy and RNAi technologies as well as the optimization of currently available therapies. He is closely involved in the design and development of clinical trials for new therapies and evolving phase 1-4 programmes. In addition, he has a major interest in the development of robust and harmonised outcome measures for haemophilia including application to research.

  • Professor Graham Foster

    Professor Foster is the Professor of Hepatology at Queen Marys, University of London and a consultant at Barts Health in East London. He trained in Medicine at Oxford and London Universities in the 1980's and completed a PhD in Molecular Biology in 1992.  Professor Foster has a long standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities and novel therapies for this disease. He leads a national study investigating community screening for viral hepatitis and supervises a laboratory research program investigating novel replication models for hepatitis C.  He is the editor of The Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is a past President of BASL, Chairman of the NHSE Hepatobiliary Clinical Reference Group, Clinical Lead for the NHSE Hepatitis C Programme and a member of a number of patient advocacy groups.

  • Dr Matthew Loose

    Matt Loose has dedicated significant time and energy to the development of tools and techniques for the analysis of long-read nanopore sequence data. To demonstrate the feasibility of this sequencer for large genomes, Matt Loose was a key member of the Nanopore WGS consortium, which released the first 35x coverage dataset of the NA12878 Human Reference Genome sequence and RNA datasets (Nature Biotechnology 2018). He has since been working to extend ultra-long sequencing methods, now reaching reads up to 2Mb in length.

     

  • Professor Tony Young

    Tony is a practicing frontline NHS surgeon, Director of Medical Innovation at Anglia Ruskin University, and has founded 4 Med-Tech start-ups. He has also co-founded the £500m Anglia Ruskin MedTech Campus.

    In 2014 he was appointed as National Clinical Director for Innovation at NHS England and in February 2016 became the first National Clinical Lead for Innovation. In this role he provides clinical leadership and support in delivering improved health outcomes in England and drives the uptake of proven innovations across the NHS, promotes economic growth through innovation and helps make the NHS the go to place on the planet for medical innovation. In 2015 he founded the NHS Clinical Entrepreneur programme. This has become the world’s largest entrepreneurial workforce development programme for clinicians.

  • Stephen Lee

    After training as a Biomedical Scientist in hospital pathology, Stephen worked as a company microbiologist until 1996 when he joined the medical device regulator now known as the UK Medicines & Healthcare Products Regulatory Agency – MHRA.

    Stephen is the chair of the European Commission’s IVD working group. This group is responsible for implementing IVD specific issues related to the new regulations including classification, performance evaluation, Common Specifications and advice and guidance on IVD regulatory issues.

    Stephen is senior policy manager at MHRA focussing on the implementation of the new regulations for in vitro diagnostic medical devices.

     

  • Professor Peter Hamilton

    Professor Peter Hamilton has recently been appointed as Head of Research, Digital and Computational Pathology Philips and Lead for Image Analysis Hub in Belfast.  Prior to this Peter lead the digital pathology programme at Queen’s University Belfast and founded the company PathXL.  

    Peter's research has focuses on digital pathology for education, computer vision and tissue bioimaging in diagnostic and molecular cancer pathology, and the high throughput quantitative analysis identification of novel tissue and cell biomarkers markers. Being a pioneer of early techniques in tissue measurement, image analysis, pathology informatics and tissue biomarker discovery, he has been published in over 120 peer reviewed publications and generated in access of £15m in grant funding to support pathology research.

     

  • Dr Manoj Ramachandran

    Manoj is a Consultant Orthopaedic Surgeon in Paediatric and Young Adult Orthopaedics and Trauma at Barts Health, based at The Royal London and Barts and The London Children’s Hospitals, London, UK. He is also Honorary Reader at Queen Mary, University of London at the Institute of Bioengineering. He qualified from King’s College School of Medicine, London with a double honours degree and proxime accessit to the University of London Gold Medal and trained in London, Los Angeles and Sydney. He has published more than 100 papers in peer-reviewed journals (including the Lancet and BMJ) and written 18 books. His non-clinical interests include clinical trials, digital health, medical devices, innovation, and charitable work. He is the co-founder of Viz.ai, an artificial intelligence start-up in medical imaging. More about Manoj at manoj.strikingly.com.

  • Adj. Professor Okan Ekinci

    Okan Ekinci, MD, MBA is the Chief Medical Officer of Roche Diagnostics Information Solutions (DIS), based in Basel, Switzerland. He is globally responsible for the Medical & Scientific Affairs of DIS, a unit that develops and offers services related to clinical decision support and data science in the context of personalized healthcare and digitalization. He brings along 20 years of experience in the healthcare sector, among which he has eight years of clinical practice in cardiology.

    Okan is an adjunct professor for Advanced Cardiac Imaging at University College Dublin Medical School, Ireland, and lectures also on Med-Tech Marketing at University of Applied Sciences Rosenheim, Germany. Okan holds an MBA from the European School of Management and Technology, Berlin, Germany, and an MD from the University of Mainz, Germany. He studied medicine at University of Izmir (Turkey), University of Mainz (Germany) and University of Texas at Houston, TX (USA).

  • Mr Chris Hudson

    Chris joined Roche in 1998 as Marketing Manager, Patient Monitoring for UK & Ireland. This business unit included Diabetes and Point of Care products used in both the Hospital and the Community. In the last 16 years Chris has held a number of Senior Leadership positions with Roche both in the UK and Global organisation.

    Chris is currently an Executive Committee member of BIVDA (British In Vitro Diagnostics Association) and the Diagnostic Industry Representative on the MTAC (Medical Technologies Advisory Committee) for NICE (National Institute for Health and Care Excellence.)

     

  • Dr Alice Ly